市場調査レポート - 55496

世界の抗菌剤市場:R&Dパイプライン・市場分析・競合環境

The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape

発行 Arrowhead Publishers
出版日 ページ情報 英文 126 Pages
価格
世界の抗菌剤市場:R&Dパイプライン・市場分析・競合環境 The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape
出版日: 2007年08月28日 ページ情報: 英文 126 Pages
概要

世界の抗感染市場は現在665億米ドルとなっており、そのうち抗菌剤は売上の半数以上を占めています。抗菌剤市場は2012年までに450億円に拡大すると見込まれています。

医療業界を専門とする米国の調査会社 Arrowhead Publishers (本社:ミネソタ州) では、世界の抗菌剤市場について調査分析し、特にR&Dパイプライン・市場分析・競合環境についてまとめた報告書 "The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape" を発行いたしました。

当報告書では、抗菌剤を分類し、それぞれの市場概要と主な製品、臨床上の効能とマーケティング、現在の市場動向などについて、概略下記の内容でお届けいたします。

第1章 エグゼクティブサマリー

第2章 細菌性疾患のイントロダクション

  • A群連鎖球菌
  • B群連鎖球菌
  • 肺炎球菌
  • インフルエンザ菌
  • 髄膜炎菌
  • メチシリン耐性黄色ブドウ球菌

第3章 患者の人口統計

第4章 主要成長牽引因子

  • 薬剤耐性
  • 新しい治療法
  • 患者人口統計
  • ワクチン
  • 臨床的成功の可能性
  • 感染症に関連する間接コスト

第5章 主要成長阻害因子

  • 過剰処方
  • 抗生物質の耐性による短期的細菌性薬剤ライフサイクル
  • 抗生物質の急な利用
  • ジェネリック医薬品
  • 治療法とワクチン

第6章 市場

  • 世界抗感染薬市場
  • 市場区分
  • 世界の抗菌剤市場
  • 主要企業
  • 市場動向

第7章 主な薬剤クラス

  • アミノグリコシド
  • カルバペネム
  • セファロスポリン
  • グリコペプチド
  • ケトライド
  • ポロペプチド
  • マクロライド
  • ペニシリン
  • オキサゾリジノン
  • キノロン

第8章 主要ブランド

第9章 今後のブランド動向

第10章 主要企業プロファイル

  • Advanced Life Sciences
  • Arpida Ltd
  • Basilea Pharmaceutica AG
  • Cerexa Inc.
  • Cubist Pharmaceuticals, Inc.
  • Targanta Therapeutics Crop.
  • Theravance

付録

図表

目次

Abstract

The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.

Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance. In addition, a number of new drug classes such as dihydrofolate reductase inhibitors (DHFR) are under evaluation which are effective in multi drug resistant organisms.

This report examines each of the antibacterial classes in turn, assessing the market potential and application in hospital and community-acquired infections.

The following product classes are analyzed in this report:

  • aminoglycosides
  • carbapenems
  • cephalosporins
  • dihydrofolate reductase inhibitors
  • glycopeptides
  • ketolides
  • lipopeptides
  • macrolides
  • penicillins
  • oxazolidinones
  • pleuromutulins
  • quinolones

The report assesses the overall antibacterial market, key classes and the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation and by leading players and their products and analyzes market trends.

The report also examines promising pipeline products and their potential impact on the prescription of current and new antibacterial agents and the future of the antibacterial market.

Key Features of this report:

  • Overview of the antibacterial market, including the main infectious agents, therapeutic drug classes and key players.
  • In-depth analysis of different classes of antibacterial agents, including leading antibacterial agents and a summary of leading brands within each class.
  • Comprehensive facts and figures for the antibacterial market, including main players and drug class break-downs.
  • Future trends in the antibacterial marketplace, driven by drug resistance and patient demographics.
  • Outlook for the antibacterial market, including the emergence of novel therapies and the impact of generics.

Table of Contents

1 EXECUTIVE SUMMARY

2 INTRODUCTION TO BACTERIAL DISEASES

  • 2.1 Group A Streptococcus (GAS)
  • 2.2 Group B Streptococcus (GBS)
  • 2.3 Streptococcus pneumoniae
  • 2.4 Haemophilus Influenzae
  • 2.5 Neisseria Meningitidis
  • 2.6 Methicillin Resistant Staphylococcus Aurens (MRSA)

3 PATIENT DEMOGRAPHICS

  • 3.1 Group A Streptococcus (GAS) Patient Statistics
  • 3.2 Group B Streptococcus (GBS) Patient Statistics
  • 3.3 Streptococcus pneumoniae Patient Statistics
  • 3.4 Haemophilus Influenzae Patient Statistics
  • 3.5 Neisseria Meningitidis Patient Statistics
  • 3.6 MRSA Patient Statistics

4 KEY DRIVERS

  • 4.1 Drug Resistance
  • 4.2 New Treatments
  • 4.3 Patient Demographics
  • 4.4 Vaccines
  • 4.5 Potential for Clinical Success
  • 4.6 Indirect Cost Associated with Infectious Diseases

5 KEY RESISTORS

  • 5.1 Over-prescription
  • 5.2 Antibiotic Resistance Leading to Short Antibacterial Drug Lifecycles
  • 5.3 Acute Use of Antibiotics
  • 5.4 Generics
  • 5.5 Curative Therapies and Vaccines

6 THE MARKET

  • 6.1 The Global Anti-infective Market
  • 6.2 Market Segments
  • 6.3 Global Antibacterial Market
    • 6.3.1 Cephalosporin Antibiotics
    • 6.3.2 Macrolide Antibiotics
    • 6.3.3 Penicillin Antibiotics
    • 6.3.4 Quinolone Antibiotics
    • 6.3.5 Other Antibiotics
  • 6.4 The Major Players
    • 6.4.1 Antibacterial Major Players in 2006
    • 6.4.2 Antibacterial Major Players in 2012
  • 6.5 Market Trends
    • 6.5.1 Antibacterial Agents by 2012

7 LEADING ANTIBACTERIAL DRUG CLASSES

  • 7.1 Aminoglycosides
  • 7.2 Carbapenems
  • 7.3 Cephalosporins
  • 7.4 Glycopeptide
  • 7.5 Ketolide
  • 7.6 Lipopeptide
  • 7.7 Macrolides
  • 7.8 Penicillins
  • 7.9 Oxazolidinones
  • 7.10 Pleuromutilins
  • 7.11 Quinolone

8 LEADING BRANDS

  • 8.1 Aminogylcoside Antibiotics
    • 8.1.1 Tygacil (Wyeth)
    • 8.1.2 Leading Aminoglycoside Sales Forecasts
  • 8.2 Carbapenem Antibiotics
    • 8.2.1 Finibax (Shionogi/ Johnson & Johnson/[Peninsula])
    • 8.2.2 Merrem/Meronem (AstraZeneca/Sumitomo Pharmaceuticals)
    • 8.2.3 Primaxin/Tieman (Merck & Co.)
    • 8.2.4 Leading Carbapenem Sales Forecasts
  • 8.3 Cephalosporins
    • 8.3.1 Ceftin/Zinnat (GlaxoSmithKline)
    • 8.3.2 Flumarin (Shionogi)
    • 8.3.3 Omnicef/Cefzon (Abbott Laboratories/Astellas)
    • 8.3.4 Rocephin (Roche)
    • 8.3.5 Leading Cephalosporin Sales Forecasts
  • 8.4 Glycopeptide Antibiotics
    • 8.4.1 Vancomycin (Shionogi/ViroPharm/[Eli Lilly])
    • 8.4.2 Targocid (Sanofi-Aventis/Astellas)
    • 8.4.3 Leading Glycopeptide Sales Forecasts
  • 8.5 Ketolide Antibiotics
    • 8.5.1 Ketek (Sanofi-Aventis/Astellas)
    • 8.5.2 Leading Ketolide Sales Forecasts
  • 8.6 Lipopeptide Antibiotics
    • 8.6.1 Cubicin (Cubist Pharmaceuticals/Novartis)
    • 8.6.2 Leading Lipopeptide Sales Forecasts
  • 8.7 Macrolide Antibiotics
    • 8.7.1 Biaxin/Biaxin XL (Abbott Laboratories)
    • 8.7.2 Zithromax/Zmax (Pfizer)
    • 8.7.3 Macrolide Sales Forecasts
  • 8.8 Oxazolidinone Antibiotics
    • 8.8.1 Zyvox/Zyvoxid (Pfizer)
    • 8.8.2 Leading Oxazolidinone Sales Forecasts
  • 8.9 Penicillin Antibiotics
    • 8.9.1 Augmentin (GlaxoSmithKline)
    • 8.9.2 Zosyn/Tazocin (Wyeth)
    • 8.9.3 Leading Penicillin Sales Forecasts
  • 8.10 Quinolone Antibiotics
    • 8.10.1 Avelox/Avalox (Astellas/Bayer/Schering-Plough)
    • 8.10.2 Levaquin/Cravit and Floxin/Tarivid (Johnson & Johnson/Daiichi Sankyo/Santen Pharmaceuticals)
    • 8.10.3 Cipro/Ciprobay/Ciproxin (Bayer/Schering-Plough)
    • 8.10.4 Leading Quinolone Sales Forecasts
  • 8.11 Pleuromutilin Antibiotics
    • 8.11.1 Altabax/Altargo (GlaxoSmithKline)
    • 8.11.2 Leading Pleuromutilin Sales Forecasts
  • 8.12 Other Antibiotics
  • 8.13 Global Antibacterial Sales Forecasts

9 FUTURE BRANDS

  • 9.1 Carbapenem Antibiotics
    • 9.1.1 Faropenem Medoxomil (Replidyne)
    • 9.1.2 PF-3,709,270 (Pfizer)
    • 9.1.3 R1558 (Roche/Daiichi-Sankyo)
  • 9.2 Cephalosporin Antibiotics
    • 9.2.1 Ceftobiprole (J&J/[Basilea])
    • 9.2.2 Ceftaroline (Cerexa/[Takeda])
  • 9.3 Dihydrofolate Reductase Inhibitor Antibiotics
    • 9.3.1 Iclaprim (Arpida/[Roche])
    • 9.3.2 AR-709 (Arpida)
  • 9.4 Glycopeptide Antibiotics
    • 9.4.1 Oritavancin (Targanta/[InterMune])
    • 9.4.2 Telavancin (Astellas/Theravance)
    • 9.4.3 Zeven (Pfizer/[Vicuron Pharmaceuticals])
  • 9.5 Ketolide Antibiotics
    • 9.5.1 Cethromycin (Advanced Life Sciences/[Abbott])
  • 9.6 Macrolides
    • 9.6.1 S-013420 (Shionogi/[Enanta Pharmaceuticals])
    • 9.6.2 Quinolone
    • 9.6.3 ABT-492 (Abbott/[Wakunga Pharmaceuticals])
    • 9.6.4 DX-619 (Daiichi-Sankyo)
    • 9.6.5 Gracevit (Daiichi-Sankyo)
    • 9.6.6 Garenoxacin (Schering-Plough/[Toyama])
    • 9.6.7 Olamufloxacin (Abbott)
  • 9.7 Other Antibiotics
    • 9.7.1 Aurograb (Novartis/[NeuTec])
    • 9.7.2 Tifacogin (Novartis/[Chiron])
    • 9.7.3 REP8839 (Replidyne)
  • 9.8 Future Global Antibacterial Sales Forecasts

10 KEY COMPANY PROFILES

  • 10.1 Advanced Life Sciences
  • 10.2 Arpida Ltd
  • 10.3 Basilea Pharmaceutica AG
  • 10.4 Cerexa Inc.
  • 10.5 Cubist Pharmaceuticals, Inc.
  • 10.6 Targanta Therapeutics Corp.
  • 10.7 Theravance

APPENDIX 3: Acronyms

TABLES

  • Table 2.1 Infectious Disease Leading Worldwide Health Burden
  • Table 4.1 Potential for Clinical Success
  • Table 6.1 Historical Sales of Leading Antibiotics 2001-2005
  • Table 7.1 Different Classes of Antibacterial Agents
  • Table 8.1 Common Bacterial Infections
  • Table 8.2 Sales Forecasts of Leading Aminoglycosides US$mn 2005A - 2012E
  • Table 8.3 Sales Forecasts of Leading Carbapenems US$2005-2012E
  • Table 8.4 Approved Cephalosporin Antibiotics
  • Table 8.5 Sales Forecasts of Cephalosporins US$mn 2005-2012E
  • Table 8.6 Sales Forecasts of Leading Glycopeptides US$mn 2005A - 2012E
  • Table 8.7 Sales Forecasts of Ketolide Antibiotics US$mn 2005 - 2012E
  • Table 8.8 Clinical Efficacy of Cubicin Versus Comparator on Pathogens
  • Table 8.9 Sales Forecasts of Leading Lipopeptides US$mn 2005A - 2012E
  • Table 8.10 Sales Forecasts of Leading Macrolides US$m 2005A - 2012E
  • Table 8.11 Sales Forecasts of Leading Oxazolidinones US$m 2005A - 2012E
  • Table 8.12 Approved Penicillins
  • Table 8.13 Sales Forecasts of Leading Penicillins US$m 2005A - 2012E
  • Table 8.14 Approved Quinolone Antibiotics
  • Table 8.15 Sales Forecasts of Leading Quinolones US$m 2005A - 2012E
  • Table 8.16 Sales Forecasts of Leading Pleuromutilins US$m 2005A - 2012E
  • Table 8.17 Sales Summary of Leading Antibacterial Agents (US$m) 2005 - 2012E
  • Table 9.1 Antibiotics in Clinical Development
  • Table 9.2 DX-619 Potent Quinolone in Vitro Against Gram Positive Pathogens
  • Table 9.3: Sales Summary of New Antibacterial Agents (US$m) 2005 - 2012E

FIGURES

  • Figure 3.1 MRSA Among ICU Patients in the US, 1995-2004
  • Figure 6.1 Global Anti-Infective Market 2006
  • Figure 6.2 Global Anti-Infective Market 2015
  • Figure 6.3 Antibacterial Sales Split - Drug Class Split 2006
  • Figure 6.4 Cephalosporin Antibiotics - Leading Drugs 2006
  • Figure 6.5 Macrolide Antibiotics - Leading Drugs 2006
  • Figure 6.6 Penicillin Antibiotics - Leading Drugs 2006
  • Figure 6.7 Quinolone Antibiotics - Leading Drugs 2006
  • Figure 6.8 Other Antibiotics - Leading Drugs 2006
  • Figure 6.9 The Major Players 2006
  • Figure 6.10 The Major Players 2012
  • Figure 6.11 Antibacterial Agents - Drug Class Split 2012
  • Figure 7.1 Site of Action of Leading Antibacterial Agents
  • Figure 9.1 Number of Drugs in Development to Treat Infectious Diseases
  • Figure 9.2 Schematic of Drug-resistant Pathogens and Market Opportunities
  • Figure 9.3 DX-619 Effective in Severe Infection Models Potent Quinolone in Vitro Against Gram Positive Pathogens
  • Figure 9.4 DC-159a Effective in Severe RTI
Back to Top